Studio 5b

Design of people-centric healthcare solutions globally.

About Studio 5b

Studio 5b is a Healthcare company. Design of people-centric healthcare solutions globally. The company has 7,985 employees. Its Indian entity Dr.Reddy's Laboratories Ltd reported revenue of ₹35,059 Cr. Studio 5b offers products and services including Healthcare Design Services and Innovation Consulting. Its focus areas include Design Services, Healthcare Innovation, People-Centric Solutions and Global Services.

Company details

People-centric healthcare experiences are designed by Studio 5b through a process that emphasizes listening to individuals problems and understanding their lives before creating solutions for healthier outcomes. Case studies demonstrate how tools like apps and ergonomic chairs are developed to address health issues, while a global approach ensures obstacles are tackled across regions such as North America, Italy, and India. Future problems are anticipated to keep solutions current and effective, fostering trust and usability in healthcare innovations.

Key Metrics
  • Indian entity revenue
    ₹35,059 Cr

    FY 2026 · +4% YoY

  • Indian entity net profit
    ₹4,158 Cr

    FY 2026 · 12% margin

  • Indian entity EBITDA
    ₹7,825 Cr

    FY 2026 · 22% margin

  • Employee Count
    7,985

Products & Services of Studio 5b

Studio 5b offers a comprehensive portfolio of products and services, including Healthcare Design Services and Innovation Consulting.

Healthcare Design Services
Design Services

Solutions for healthcare experiences are created with an emphasis on user problems and healthier outcomes.

Innovation Consulting
Consulting Services

Future-oriented solutions are developed to address global health obstacles and maintain relevance.

Apps and channels of Studio 5b

its YouTube channel Studio 5b has 11 subscribers and 2 videos.

Studio 5b
YouTube 11 subscribers 2 videos Science & Technology
Open channel

Videos from Studio 5b

The most watched videos on Studio 5b's YouTube channel, Studio 5b (11 subscribers). Click a video to play it here.

Role of Design Thinking in Transforming Organization | Studio 5b webinar
485 views
Experience vs Product - The Future of Product Companies | Studio 5b webinar
143 views

More on Studio 5b.

Board of directors of Dr.Reddy's Laboratories Ltd (Studio 5b)

Dr.Reddy's Laboratories Ltd is the primary company behind Studio 5b. The board of Dr.Reddy's Laboratories Ltd currently have 13 directors; the longest-serving is Venkateswara Prasad Gunupati, appointed in 1986. 24 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Venkateswara Prasad Gunupati
DIN 00057433
Managing Director08 Apr 198640 yrs 6 moDr.Reddy's Laboratories Ltd
Satish Reddy Kallam
DIN 00129701
Whole-time director18 Jan 199333 yrs 9 moDr.Reddy's Laboratories Ltd
Leo Puri
DIN 01764813
Director25 Oct 20187 yrs 11 moDr.Reddy's Laboratories Ltd
Shikha Sanjaya Sharma
DIN 00043265
Director31 Jan 20197 yrs 8 moDr.Reddy's Laboratories Ltd
Erez Israeli
DIN 08563726
CEO01 Aug 20197 yrs 2 moDr.Reddy's Laboratories Ltd
Kodumudi Pranatharthiharan Krishnan
DIN 01099097
Director07 Jan 20224 yrs 9 moDr.Reddy's Laboratories Ltd
Penny Chan Wan
DIN 09479493
Director28 Jan 20224 yrs 8 moDr.Reddy's Laboratories Ltd
Arun Madhavan Kumar
DIN 09665138
Director01 Aug 20224 yrs 2 moDr.Reddy's Laboratories Ltd
Claudio Dr. Albrecht
DIN 10109819
Director10 May 20233 yrs 5 moDr.Reddy's Laboratories Ltd
Alpna Hansraj Seth
DIN 01183914
Director19 Sep 20233 yrs 1 moDr.Reddy's Laboratories Ltd
Sanjiv Soshil Mehta
DIN 06699923
Director29 Dec 20232 yrs 9 moDr.Reddy's Laboratories Ltd
Venkatanarasimham Mannam
DIN 02677423
CFO01 Aug 20242 yrs 2 moDr.Reddy's Laboratories Ltd
Srikanth Velamakanni
DIN 01722758
Additional Director01 Jul 20263 moDr.Reddy's Laboratories Ltd

Financials of Studio 5b

Figures of Dr.Reddy's Laboratories Ltd, the primary company behind Studio 5b, for FY 2026. Revenue was ₹35,059 Cr (+4% year on year). Net profit was ₹4,158 Cr (12% margin). EBITDA was ₹7,825 Cr (22% margin). Revenue has grown at a compounded annual rate of +11% over three years and +13% over five years.

  • ₹35,059 CrRevenue · FY 2026 · +4% YoY
  • ₹4,158 CrNet profit · 12% margin
  • ₹7,825 CrEBITDA · 22% margin
  • ₹83.47 CrPaid-up capital
  • 7,985Employees (provident fund records)
  • +11%Revenue CAGR, 3 years
  • +13%Revenue CAGR, 5 years

Balance sheet, profit and loss, cash flow and ratios of Dr.Reddy's Laboratories Ltd are on its company page.

Premium access

Detailed financial statements for Studio 5b

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Studio 5B

Dr. Reddy's Laboratories: Co Gets DCGI Approval For Zytorvi® (Toripalimab) For Advanced Esophageal Squamous Cell Carcinoma; This Marks The Second Approved Use In India, Expanding Beyond Nasopharyngeal Carcinoma; Clinical Trials Indicate A 42% Decrease In Risk Of Disease Or Death.
Exchange Update • 1 day ago
DRREDDY: Rs. 24.65 Crores NSE Block Trade; for ~ 202,198 Shares, at Rs. 1219.00
Exchange Update • 22 days ago
Dr. Reddy's Laboratories: Co CFO Is Sure About "High-Teen" Revenue Growth For FY27 And Later; The Company Has The Ability To Acquire Up To $2B In "Strategic Assets" And Is Aiming To Buy Firms And Brands Across Various Therapies.
Exchange Update • 23 days ago
Dr Reddy's: CFO Expresses Interest In Acquiring Any Size Of Companies, Emphasizing The Importance Of The Right Assets.
Exchange Update • 23 days ago
Dr. Reddy's Laboratories: Unveils New Products To Boost Growth; Targets 25% EBITDA Margin Long-Term And 20% For FY27.
Exchange Update • 23 days ago
Dr Reddy's: Company's Co CFO Highlights Plans to Submit New PDT Applications in Emerging Markets; Nicotine Products Expected to Boost Sales in Europe by FY27.
Exchange Update • 23 days ago
Dr. Reddy's Laboratories: Sees Growth Potential With 3 Complex Generic Products In The US; Plans To Introduce 20-25 New Products In FY27; Anticipates Strong US Sales Growth For FY27
Exchange Update • 23 days ago
Dr Reddy’s: Nomura on Dr Reddy’s Buy, Target Price ₹1,740, as the company awaits USFDA clearance/EIR for its biologics plant and Abatacept IV approval by Dec 18, 2026; management expects a positive outcome, supported by recent Rituximab approval and validated commercial-scale batches, with sufficient capacity and no scale-up concerns; sees strong medium- to long-term biosimilar opportunities from patent expiries and easing regulation.
Exchange Update • 24 days ago
Premium access

Complete news archive for Studio 5b

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Studio 5b

Studio 5b has 7,985 employees.

The primary company behind Studio 5b, Dr.Reddy's Laboratories Ltd, reported revenue of ₹35,059 Cr for FY 2026, up 4% year on year.

People-centric healthcare experiences are designed by Studio 5b through a process that emphasizes listening to individuals problems and understanding their lives before creating solutions for healthier outcomes. Case studies demonstrate how tools like apps and ergonomic chairs are developed to address health issues, while a global approach ensures obstacles are tackled across regions such as North America, Italy, and India. Future problems are anticipated to keep solutions current and effective, fostering trust and usability in healthcare innovations.

Studio 5b offers Healthcare Design Services and Innovation Consulting.

Studio 5b operates through Dr.Reddy's Laboratories Ltd.

The legal entities of Studio 5b currently have 15 directors, including Kodumudi Pranatharthiharan Krishnan, Venkatanarasimham Mannam, Leo Puri and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available